Shares of argenx SE (ARGX) are up more than 8% Monday morning.
On Friday, the FDA had approved argenx's VYVGARTô for the treatment of adults patients with generalized myasthenia gravis.
Generalized myasthenia gravis is a rare and chronic neuromuscular disease characterized by debilitating and potentially life-threatening muscle weakness.
ARGX is at $337.02 currently. It has traded in the range of $248.21- $382.15 in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.